Neurology

One round of investigational combination treatment may be more effective than long-term treatment for multiple sclerosis.

Patients with MS administered ozanimod experienced less relapses over 1 year.

A new therapeutic agent prevented neuronal damage and preserved function in an MS mouse model.

Liver injury reported in patients with oral multiple sclerosis drug.

The Cleveland Clinic received multi-million dollar awards to further multiple sclerosis and bone marrow failure syndrome research.

Current stage 3 trials for multiple sclerosis medications may address several unmet needs in the patient population.

Roughly half of MS patients had hyposmia at the beginning of the study.

95% of survey respondents support medical marijuana treatment for multiple sclerosis.

A change from fingolimod to alemtuzumab caused significant disease activity in patients with MS.

Treatment with ST266 linked to increased survival of retinal ganglion cells in patients with multiple sclerosis.

Female first-degree relatives face the highest risk of developing multiple sclerosis.

MicroRNAs could monitor the severity of MS in the future.

Ocrelizumab may effectively treat patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Top articles of the week from Specialty Pharmacy Times.

Repetitive transcranial magnet stimulation shows promise treating symptoms of MS.

Working memory was improved in patients with MS who underwent repetitive transcranial magnetic stimulation.

Teva loses patent infringement litigations for Copaxone.

Ocrelizumab reduced disease activity in patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Dalfampridine extended-release tablets deemed bioequivalent of Amprya.

Dalfampridine extended-release tablets is the bioequivalent of Amprya.

Conflicting evidence surrounds the association between multiple sclerosis and uveitis.

The FDA has given final approval to Aurobindo Pharma Limited for dalfampridine extended-release tablets (10 mg).

No evidence of disease activity criteria in multiple sclerosis may need to be reconsidered.

Without a special license, researchers can only conduct observational studies that include cannabis.

High-risk family members more likely to have early subclinical manifestations of MS.